Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Brown adipose tissue-derived exosomes ameliorate obesity-related hypertension via HuR-mediated restoration of endothelial function.

Hu X., Li H., Dou Y., Lv Z., Zhang Y., Zou T.

Animal Study on Chronic Inflammation, published in Int J Obes (Lond) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Obes (Lond) (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41514046
DOI
10.1038/s41366-025-02015-w

Abstract (original English)

Obesity-related hypertension (OH) is driven by endothelial dysfunction, chronic inflammation, and oxidative stress, yet effective targeted therapies are lacking. This study aims to investigate the mechanisms by which brown adipose tissue-derived exosomes (BAT-Exos) improve vascular endothelial function in OH via HuR protein delivery. Rat models with OH and palmitic acid-treated endothelial cell injury models were established. BAT-Exos were compared with white adipose tissue-derived exosomes (WAT-Exos) for therapeutic efficacy. In vitro, primary endothelial cells isolated from rat aortas were treated with palmitic acid to induce injury, followed by pre-treatment with BAT-Exos or WAT-Exos. Inflammatory cytokines, adhesion molecules, oxidative stress markers, eNOS activity, and nitric oxide (NO) levels were measured. BAT-Exos exert superior therapeutic effects compared to WAT-Exos in both in vivo and in vitro models of OH. In rat model of high-fat-diet-induced OH, BAT-Exos improved metabolic profiles, lowered blood pressure, and alleviated vascular remodeling, while reducing inflammation and restoring eNOS activity. In vitro, BAT-Exos significantly mitigated palmitic acid-induced endothelial dysfunction by suppressing pro-inflammatory cytokines, adhesion molecules, and oxidative stress markers, while enhancing nitric oxide production. These findings confirm HuR as a key therapeuti

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsRatsHypertensionObesityMaleEndothelium, VascularExosomesAdipose Tissue, BrownDisease Models, AnimalOxidative Stress

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research